Make the NEX move for your patients with LOPD
NEXVIAZYME is the #1 prescribed treatment for LOPD1,*
The majority of ERT-treated patients have switched to NEXVIAZYME1,*
*Prescription data as of February 2024.
Sanofi may be able to help your patients start treatment
The QuickStart Program
The QuickStart CareConnectPSS® program provides NEXVIAZYME to eligible,* commercially-insured patients. Patients can receive NEXVIAZYME at no charge while authorization is being reviewed, or in the event of coverage delays or denials.
How to apply
- The patient’s healthcare provider must send the application for QuickStart (as indicated on the enrollment form)
- Once coverage has been obtained, the CareConnectPSS team will work with you and your patient to transition to commercial product
Looking to learn more? Ready to start an application?
Go to CareConnectPSS.com
Co-Pay Program
The CareConnectPSS Copay Assistance Program helps eligible patients† in the United States who are prescribed NEXVIAZYME pay for their eligible out-of-pocket drug costs and certain infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including copays, coinsurance, and deductibles.
- To participate in this program, your patients must complete an enrollment application
- Once enrolled, Sanofi will cover 100% of their eligible out-of-pocket NEXVIAZYME drug costs, up to the program maximum
Once they are enrolled in CareConnectPSS, work with your patient to apply for the Copay Assistance Program. View paper application here.
Patient Assistance Program
If your patient does not have insurance, or their insurance has denied coverage for NEXVIAZYME, they may be eligible to receive NEXVIAZYME through the CareConnectPSS Patient Assistance Program (PAP). To see if they qualify, patients must complete a CareConnectPSS PAP application with their doctor.
*Certain eligibility restrictions apply. Eligible patients may receive up to 4 infusions of NEXVIAZYME; in certain circumstances, eligibility may be extended. QuickStart is not mandatory, you can still get support from CareConnectPSS if you choose not to participate or if your patient is not eligible, call the CareConnectPSS Team directly at 1-800-745-4447, Option 3 to learn more.
†Patients whose medication or infusion-related costs are covered by a state or federal health care program, including but not limited to Medicare, Medicare Part D, Medigap, Medicaid, Veterans Affairs (VA), Department of Defense (DoD), or TRICARE, are not eligible for the Co-Pay Program. Patients must live in the US or a US territory. Patients must be eligible under applicable state law(s). Other terms and conditions of the Program apply. Co-Pay Program does not cover or provide support for MD office visits/evaluations, nursing services/observation periods, bloodwork, x-rays or other testing, pre-medications/other medications, transportation or other related services associated with treatment. In accordance with state law, infusion-related costs are not covered for commercially-insured patients residing in MA or RI. Sanofi reserves the right to modify or discontinue the programs at any time without notice. Savings may vary depending on patients’ out-of-pocket costs. All program details provided upon registration.
|
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS Hypersensitivity Reactions including Anaphylaxis Patients treated with NEXVIAZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, NEXVIAZYME should be discontinued immediately and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to NEXVIAZYME may be considered. Infusion-Associated Reactions (IARs) Patients treated with NEXVIAZYME have experienced severe IARs. If severe IARs occur, consider immediate discontinuation of NEXVIAZYME, initiation of appropriate medical treatment, and the benefits and risks of readministering NEXVIAZYME following severe IARs. Patients with an acute underlying illness at the time of NEXVIAZYME infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs. Risk of Acute Cardiorespiratory Failure in Susceptible Patients Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during NEXVIAZYME infusion. More frequent monitoring of vitals should be performed during NEXVIAZYME infusion. |
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Prior to NEXVIAZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. The risks and benefits of readministering NEXVIAZYME following severe hypersensitivity reaction (including anaphylaxis) should be considered. If a mild or moderate hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily stopped.
Infusion-Associated Reactions: See Boxed WARNING. IARs may still occur in patients after receiving pretreatment. If mild or moderate IARs occur regardless of pretreatment, decreasing the infusion rate or temporarily stopping the infusion may ameliorate the symptoms.
Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.
ADVERSE REACTIONS
The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, arthralgia, dizziness, myalgia, pruritus, vomiting, dyspnea, erythema, paresthesia and urticaria.
INDICATION
NEXVIAZYME (avalglucosidase alfa-ngpt) is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Please see full Prescribing Information for complete details, including Boxed WARNING.
Reference: 1. Data on file. Genzyme Corporation.
|
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS Hypersensitivity Reactions including Anaphylaxis Patients treated with NEXVIAZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, NEXVIAZYME should be discontinued immediately and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to NEXVIAZYME may be considered. Infusion-Associated Reactions (IARs) Patients treated with NEXVIAZYME have experienced severe IARs. If severe IARs occur, consider immediate discontinuation of NEXVIAZYME, initiation of appropriate medical treatment, and the benefits and risks of readministering NEXVIAZYME following severe IARs. Patients with an acute underlying illness at the time of NEXVIAZYME infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs. Risk of Acute Cardiorespiratory Failure in Susceptible Patients Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during NEXVIAZYME infusion. More frequent monitoring of vitals should be performed during NEXVIAZYME infusion. |
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Prior to NEXVIAZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. The risks and benefits of readministering NEXVIAZYME following severe hypersensitivity reaction (including anaphylaxis) should be considered. If a mild or moderate hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily stopped.
Infusion-Associated Reactions: See Boxed WARNING. IARs may still occur in patients after receiving pretreatment. If mild or moderate IARs occur regardless of pretreatment, decreasing the infusion rate or temporarily stopping the infusion may ameliorate the symptoms.
Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.
ADVERSE REACTIONS
The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, arthralgia, dizziness, myalgia, pruritus, vomiting, dyspnea, erythema, paresthesia and urticaria.
INDICATION
NEXVIAZYME (avalglucosidase alfa-ngpt) is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Please see full Prescribing Information for complete details, including Boxed WARNING.
Reference: 1. Data on file. Genzyme Corporation.